Last reviewed · How we verify
doxorubicine + cyclophosphamide sequential
Doxorubicin is a topoisomerase II inhibitor that intercalates DNA, while cyclophosphamide is an alkylating agent that cross-links DNA.
Doxorubicin is a topoisomerase II inhibitor that intercalates DNA, while cyclophosphamide is an alkylating agent that cross-links DNA. Used for Breast cancer, Lymphoma.
At a glance
| Generic name | doxorubicine + cyclophosphamide sequential |
|---|---|
| Sponsor | Sanofi |
| Drug class | anthracycline antibiotic + alkylating agent |
| Target | topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Doxorubicin works by inhibiting the enzyme topoisomerase II, which is necessary for DNA replication and transcription. This leads to DNA damage and ultimately cell death. Cyclophosphamide, on the other hand, forms cross-links between DNA strands, which prevents DNA replication and transcription, leading to cell death.
Approved indications
- Breast cancer
- Lymphoma
Common side effects
- Myelosuppression
- Cardiotoxicity
- Nausea and vomiting
- Hair loss
Key clinical trials
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (PHASE1)
- Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer (NA)
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (PHASE2)
- A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer (PHASE1)
- Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (PHASE2)
- Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma (PHASE2)
- Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (PHASE3)
- Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- doxorubicine + cyclophosphamide sequential CI brief — competitive landscape report
- doxorubicine + cyclophosphamide sequential updates RSS · CI watch RSS
- Sanofi portfolio CI